Expert consensus on brachytherapy for recurrent cervical cancer
10.3760/cma.j.cn113030-20200409-00170
- VernacularTitle:复发宫颈癌近距离治疗专家共识
- Author:
Ping JIANG
1
;
Fuquan ZHANG
;
Guanghui CHENG
;
Ruoyu WANG
;
Baosheng SUN
;
Tiejun WANG
;
Yunyan ZHANG
;
Ang QU
;
Junjie WANG
Author Information
1. 北京大学第三医院放疗科 100191
- From:
Chinese Journal of Radiation Oncology
2020;29(9):721-729
- CountryChina
- Language:Chinese
-
Abstract:
The main treatment options for cervical cancer include surgery and/or radiotherapy combined with chemotherapy. Radiotherapy consists of external beam radiotherapy and brachytherapy (BT). BT contains high-dose-rate (HDR-BT) and low-dose-rate brachytherapy (LDR-BT). The prognosis of cervical cancer is relatively good. However, some patients experience substantial treatment failures, such as intra-pelvic and/or extra-pelvic recurrences. Recurrent cervical cancer (RCC) has poor prognosis due to lack of effective and safe approach. In 2002, Professor Wang Junjie introduced CT-guidance into the field of LDR-BT, and fully applied 3D printing technology in BT in 2015, which met the requirement of preoperative LDR-BT planning, and significantly improving the precision, quality and efficiency of BT. In 2018, Professor Wang Junjie proposed the concept of stereotactic ablation brachytherapy (SABT). Chinese experts have attempted to treat RCC with BT for nearly two decades and accumulated certain clinical experience. Based on the 3D-printing template (3D-PT) assisted CT-guidance, the standard and consensus of BT for RCC were established, including the indications, dosimetric requirements, technological procedures and radiation protection, etc. At present, there is still a lack of phage Ⅲ clinical and evidence-based medicine for the treatment of RCC with 3D-PT guidance, which requires prospective multi-center, randomized studies to improve the evidence-based level of BT.
